Sanofi Sees Shanghai Alliances Key To Open Innovation
This article was originally published in PharmAsia News
Accelerating research productivity, establishing bilateral cooperation and collaborating with more external partners are some of Sanofi’s aim for its new Asia-Pacific research center in Shanghai, says its head of R&D in Asia.
You may also be interested in...
Regulatory pressure to fully approve the first COVID-19 vaccine in China is mounting as top officials tour an inspection agency and two leading manufacturers.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.